Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings.

Abstract

Aim: To describe burden of chemotherapy-induced myelosuppression among chemotherapy-treated patients with extensive-stage small cell lung cancer (ES-SCLC). Materials & methods: Occurrence of grade ≥3 myelosuppressive hematological adverse events (HAEs), treatment patternsand healthcare resource utilization (HCRU) after chemotherapy initiation were evaluated using data from TheUS Oncology Network and Non-network clinics (1/1/2015-12/31/2020). Results: Among patients with laboratory values (Network: N=1,374/1,574; Non-network: N=661/959), over half-experienced grade ≥3 HAEs after chemotherapy initiation (Network=56.6%; Non-network=64.1%), and approximately one-third had grade ≥3 HAEs in at least two lineages (Network=33.0%; Non-network=31.3%). Patients with grade ≥3 HAEs had greater dose reductions, treatment delaysand HCRU than those without. Conclusion: Myelosuppression is a burden to patients with ES-SCLC treated with chemotherapy and the healthcare system.